[Page Banner Image]

The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.

The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.

[HRule Image]

Molecular Biology — January 2005

bioMérieux has exercised an option to develop diagnostic products for certain undisclosed disease targets using Gen-Probe's patented ribosomal RNA technologies, pursuant to terms of an agreement first disclosed on October 6, 2004.

Gen-Probe has licensed technology from AdnaGen that enables detection of rare, circulating tumor cells that are an early event in cancer metastasis. First, cancerous cells are isolated from healthy cells using a mixture of specific monoclonal antibodies linked to magnetic particles. Second, the RNA inside the captured cells is released and amplified to identify expressed genes that are markers for specific cancers. Gen-Probe has also licensed from Corixa the rights to develop molecular diagnostic tests for approximately 50 potential genetic markers in the areas of prostate, ovarian, cervical, kidney, lung and colon cancer.

Genelex Corporation has developed the personal Drug Reaction DNA Testing kits available via their website without prescription. Consumers receive their results by mail and are urged to share the findings with their physicians and pharmacists. Patients may also obtain a personalized report based on the medicines they are currently taking. The test measures CYP2C9 associated with gene-based poor metabolism of prescription drugs.

Roche Diagnostics received FDA clearance to market the microarray-based test, the AmpliChip CYP450 Test. This test, which is powered by Affymetrix microarray technology, analyses a patient's Cytochrome P450 2D6 and 2C19 genotypes from genomic DNA extracted from a blood sample. The multiple variations in the CYP2D6 gene can result in poor, intermediate, extensive, or ultra- rapid metabolism of CYP2D6-dependent drugs from a variety of classes, including anti-depressants, anti-psychotics, anti-arrhythmics, beta-blockers, pain medications, anti-emetics, and some anti-cancer drugs. Variations in the CYP2C19 gene result in either normal or poor metabolism of CYP2C19-dependent drugs from a variety of classes, including anti-convulsants, proton pump inhibitors, benzodiazepines, and anti-malarials.

ViroLogic, Inc. is developing its eTAG System to predict treatment outcomes for patients with metastatic colorectal cancer. In a study, conducted at Princess Margaret Hospital in Toronto, the eTAG assay correlated with disease stability or disease progression in 18 metastatic colorectal cancer patients being treated with erlotinib (Tarceva).

[HRule Image]

* Molecular Biology - December 2004
* Molecular Biology - November 2004
* Molecular Biology - October 2004
* Molecular Biology - September 2004
* Molecular Biology - Summer 2004
* Molecular Biology - May 2004
* Molecular Biology - April 2004
* Molecular Biology - March 2004
* Molecular Biology - February 2004
* Molecular Biology - January 2004
* Molecular Biology - November 2003
* Molecular Biology - October 2003
* Molecular Biology - September 2003
* Molecular Biology - May 2003
* Molecular Biology - April 2003
* Molecular Biology - March 2003
* Molecular Biology - April 04003
* Molecular Biology - January 2003
* Molecular Biology - December 2002
* Molecular Biology - November 2002
* Molecular Biology - October 2002
* Molecular Biology - September 2002
* Molecular Biology - Summer 2002
* Molecular Biology - June 2002
* Molecular Biology - May 2002
* Molecular Biology - April 2002
* Molecular Biology - March 2002
* Molecular Biology - April 04002
* Molecular Biology - January 2002
* Molecular Biology - December 2001
* Molecular Biology - November 2001
* Molecular Biology - October 2001
* Molecular Biology - September 2001
* Molecular Biology - Summer 2001
* Molecular Biology - May 2001
* Molecular Biology - April 2001
* Molecular Biology - March 2001
* Molecular Biology - April 04001
* Molecular Biology - January 2001
* Molecular Biology - December 2000
* Molecular Biology - November 2000
* Molecular Biology - October 2000
* Molecular Biology - September 2000
* Molecular Biology - July - August 2000
* Molecular Biology - June 2000
* Molecular Biology - May 2000
* Molecular Biology - April 2000
* Molecular Biology - March 2000
* Molecular Biology - Febuary 2000
* Molecular Biology - January 2000
* Molecular Biology - December 1999
* Molecular Biology - November 1999
* Molecular Biology - October 1999
* Molecular Biology - September 1999

[HRule Image]

Home | Company Profile | Services | Research Reports Available
Product Developments Worldwide | Research News | Health Care in Canada
Information Technology and Healthcare | Molecular Biology | Links

[HRule Image]
Send mail to stratcom@pagebleu.com with questions or comments about this web site.

Concept and Design Blue Page Productions
Copyright © 1996-2005 STRATCOM

Last modified: February 3, 2005